ClinConnect ClinConnect Logo
Search / Trial NCT06604130

Plasma Exosome RNA to Diagnose Prostate Cancer

Launched by XIJING HOSPITAL · Sep 17, 2024

Trial Information

Current as of August 20, 2025

Enrolling by invitation

Keywords

Prostate Cancer Rna Diagnosis Combination

ClinConnect Summary

No description provided

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • 1. Blood prostate-specific antigen PSA\>4ng/dl;
  • 2. Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging, and PSMA PET/CT examination.
  • 3. The patient is willing to undergo prostate biopsy.
  • Exclusion Criteria:
  • 1. Previous diagnosis of prostate cancer through prostate biopsy;
  • 2. History of other malignant tumors in the past two years;
  • 3. According to the research physician\'s judgment, serious complications may occur and affect the normal conduct of the experiment

About Xijing Hospital

Xijing Hospital, a prominent medical institution affiliated with the Fourth Military Medical University in Xi'an, China, is dedicated to advancing healthcare through innovative clinical research. Renowned for its comprehensive range of medical services and expertise in various specialties, Xijing Hospital actively sponsors clinical trials aimed at evaluating new therapies, improving patient outcomes, and contributing to scientific knowledge. With a commitment to ethical standards and patient safety, the hospital fosters collaboration among multidisciplinary teams to drive forward the development of effective treatment options that address critical health challenges.

Locations

Xian, Shaanxi, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported